| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Hoth Therapeutics Inc (NASDAQ: HOTH)
HOTH Technical Analysis
4
| As on 9th Jun 2023 HOTH STOCK Price closed @ 3.00 and we RECOMMEND Buy for LONG-TERM with Stoploss of 0.87 & Strong Buy for SHORT-TERM with Stoploss of 0.69 we also expect STOCK to react on Following IMPORTANT LEVELS. |
HOTHSTOCK Price
| Open | 3.12 | Change | Price | % |
| High | 3.23 | 1 Day | -0.20 | -6.25 |
| Low | 2.75 | 1 Week | 1.41 | 88.68 |
| Close | 3.00 | 1 Month | 1.10 | 57.89 |
| Volume | 536600 | 1 Year | 2.26 | 305.41 |
| 52 Week High 10.72 | 52 Week Low 0.24 | ||||
NASDAQ USA Most Active Stocks
| TSLA | 244.40 | 4.06% |
| TTOO | 0.07 | -12.50% |
| SOFI | 8.18 | 0.74% |
| FFIE | 0.33 | 6.45% |
| PONO | 1.72 | 2.38% |
| AMD | 124.92 | 3.20% |
| IDEX | 0.06 | 0.00% |
| NKLA | 0.70 | 14.75% |
| AMZN | 123.43 | -0.66% |
| AAPL | 180.96 | 0.22% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
| HOTH Daily Charts |
HOTH Intraday Charts |
Whats New @ Bazaartrend |
HOTH Free Analysis |
|
|
HOTH Important Levels Intraday
| RESISTANCE | 3.92 |
| RESISTANCE | 3.63 |
| RESISTANCE | 3.44 |
| RESISTANCE | 3.26 |
| SUPPORT | 2.74 |
| SUPPORT | 2.56 |
| SUPPORT | 2.37 |
| SUPPORT | 2.08 |
HOTH Forecast May 2024
| 4th UP Forecast | 4.33 |
| 3rd UP Forecast | 3.9 |
| 2nd UP Forecast | 3.64 |
| 1st UP Forecast | 3.38 |
| 1st DOWN Forecast | 2.62 |
| 2nd DOWN Forecast | 2.36 |
| 3rd DOWN Forecast | 2.1 |
| 4th DOWN Forecast | 1.67 |
HOTH Weekly Forecast
| 4th UP Forecast | 3.23 |
| 3rd UP Forecast | 3.16 |
| 2nd UP Forecast | 3.11 |
| 1st UP Forecast | 3.07 |
| 1st DOWN Forecast | 2.93 |
| 2nd DOWN Forecast | 2.89 |
| 3rd DOWN Forecast | 2.84 |
| 4th DOWN Forecast | 2.77 |
HOTH Forecast2024
| 4th UP Forecast | 26.63 |
| 3rd UP Forecast | 19.05 |
| 2nd UP Forecast | 14.37 |
| 1st UP Forecast | 9.68 |
| 1st DOWN Forecast | -3.68 |
| 2nd DOWN Forecast | -8.37 |
| 3rd DOWN Forecast | -13.05 |
| 4th DOWN Forecast | -20.63 |
Hoth Therapeutics Inc ( NASDAQ USA Symbol : HOTH )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
HOTH Business Profile
Hoth Therapeutics, Inc., a biopharmaceutical company, focuses on developing therapies for dermatological disorders. The company focuses on therapies for patients suffering from indications, including eczema, chronic wounds, psoriasis, asthma, and acne. Its pipeline portfolio includes HT-001, a topical formulation for the treatment of mild to moderate rash and skin disorders associated with initial and repeat courses of tyrosine kinase inhibitor/epidermal growth factor receptor (EGFR) inhibitor therapy; HT-002 to treat illness associated with SARS-CoV-2 infection; HT-003D for the topical treatment in acne and psoriasis applications; HT-003IB to treat inflammatory bowel diseases; HT-004 for the treatment of asthma, atopic dermatitis, and other allergic diseases; HT-005 Z-PODS to treat cutaneous lupus erythematosus; HT-006 for treatment of multiple bacterial pathogens. The company has license agreements with the George Washington University; the University of Maryland; Isoprene Pharmaceuticals, Inc.; the North Carolina State University; Chelexa BioSciences, Inc.; and the University of Cincinnati. It also has a partnership agreement with Zylö Therapeutics Inc. co-develop a new topical treatment for patients with Cutaneous Lupus Erythematosu, a chronic autoimmune disease that affects the skin and is associated with a significant burden on patient quality of life; and research collaboration agreement with Weill Cornell Medicine to continue the advancement of HT-003 for acne treatment research. Hoth Therapeutics, Inc. was incorporated in 2017 and is headquartered in New York, New York. Address: 1 Rockefeller Plaza, New York, NY, United States, 10020
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service